Published in Ann Oncol on March 11, 2008
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer (2009) 1.30
Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One (2011) 1.27
Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release (2012) 1.18
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
Leptomeningeal metastases in breast cancer. Am J Cancer Res (2013) 1.00
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer (2012) 1.00
Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 0.99
Leptomeningeal metastasis in breast cancer - a systematic review. Oncotarget (2016) 0.97
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer (2011) 0.96
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review. Breast Cancer Res (2015) 0.95
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist (2013) 0.93
Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J Neurooncol (2015) 0.90
Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience (2013) 0.89
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer (2012) 0.88
An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol (2013) 0.87
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med (2014) 0.86
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist (2015) 0.84
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist (2012) 0.83
Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat (2012) 0.82
Pathological confirmation of primary lung cancer following breast cancer. Lung Cancer (2009) 0.82
Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases. BMC Cancer (2013) 0.81
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med (2014) 0.80
Clinical outcome in gamma knife radiosurgery for metastatic brain tumors from the primary breast cancer : prognostic factors in local treatment failure and survival. J Korean Neurosurg Soc (2013) 0.79
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol (2010) 0.79
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.79
Factors affecting receipt of chemotherapy in women with breast cancer. Int J Womens Health (2010) 0.79
Assessment of prognostic scores in brain metastases from breast cancer. Neuro Oncol (2013) 0.79
Conus medullaris metastasis in breast cancer: report of a case and a review of the literature. Surg Today (2012) 0.78
Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clin Exp Metastasis (2016) 0.77
CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. J Cancer Res Clin Oncol (2012) 0.76
Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer. J Cancer Res Clin Oncol (2013) 0.76
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncol (2016) 0.76
Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China. Arch Med Sci (2015) 0.75
Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer. J Cancer Epidemiol (2012) 0.75
Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain. Case Rep Oncol Med (2016) 0.75
Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis. Breast Care (Basel) (2015) 0.75
Methods and results of local treatment of brain metastases in patients with breast cancer. Contemp Oncol (Pozn) (2017) 0.75
Overview of the CLEOPATRA Trial: Implications for Advanced Practitioners. J Adv Pract Oncol (2016) 0.75
Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy? J Neurooncol (2017) 0.75
Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat (2017) 0.75
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Oral maintenance therapy for cholera in adults. Lancet (1968) 2.53
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Quantum simulation of frustrated Ising spins with trapped ions. Nature (2010) 2.16
Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res (2001) 2.16
Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol (1995) 2.08
Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene (2007) 1.98
Trastuzumab: triumphs and tribulations. Oncogene (2007) 1.94
Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res (1995) 1.92
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol (2006) 1.91
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
The natural history of breast cancer patients with brain metastases. Cancer (1979) 1.82
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am (1998) 1.77
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med (1994) 1.66
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (1979) 1.62
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg (1999) 1.60
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene (2011) 1.59
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol (1998) 1.58
Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer (1998) 1.57
Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer (1991) 1.57
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer (2001) 1.57
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol (2006) 1.55
Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol (2010) 1.55
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol (2007) 1.54
Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer. Ann Intern Med (1997) 1.51
Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. Proc Natl Acad Sci U S A (2000) 1.50
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am (1999) 1.48
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol (1998) 1.48
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol (2000) 1.46
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol (2011) 1.45
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res (1997) 1.43
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg (1989) 1.41
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg (1998) 1.40
Discouraging news for high-dose chemotherapy in high-risk breast cancer. Lancet (1998) 1.40
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol (1994) 1.39
Clinical course of breast cancer patients with liver metastases. J Clin Oncol (1987) 1.32
Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer (1992) 1.31
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (2001) 1.28
Entanglement and tunable spin-spin couplings between trapped ions using multiple transverse modes. Phys Rev Lett (2009) 1.26
Multimodal treatment of locoregionally advanced breast cancer. Cancer (1983) 1.26
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol (2006) 1.25
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol (1999) 1.25
EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2001) 1.21
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat (1998) 1.20
Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer (1993) 1.20
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer (1999) 1.19
Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res (1988) 1.19
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer (2005) 1.18
Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol (2013) 1.18
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist (2001) 1.17
Impact of a cash-for-work programme on food consumption and nutrition among women and children facing food insecurity in rural Bangladesh. Bull World Health Organ (2010) 1.17
Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs (1994) 1.16
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol (2013) 1.14
Fourteen years of shigellosis in Dhaka: an epidemiological analysis. Int J Epidemiol (1985) 1.14
Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol (1999) 1.13
The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer (2004) 1.12
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol (2009) 1.12
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer (2010) 1.11
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (1996) 1.10
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2000) 1.09